Full Breakdown
Breakthrough in Sleeping Sickness Treatment: Acoziborole Approved
3/2/2026, 10:17:36 PM
New Drug Approval and Its Significance
On March 2, 2026, the European Medicines Agency (EMA) committee recommended the approval of acoziborole, a groundbreaking single-dose oral treatment for sleeping sickness, also known as human African trypanosomiasis (HAT). Developed by Sanofi in collaboration with the Drugs for Neglected Diseases initiative (DNDi), this treatment is poised to significantly enhance efforts to eliminate the disease, particularly in the Democratic Republic of the Congo (DRC), where the majority of cases occur.
Acoziborole is administered as three pills taken together in a single dose, contrasting sharply with existing treatments that require lengthy hospital stays and painful procedures, such as spinal taps. This new regimen is expected to improve accessibility for patients in remote areas, where the disease is most prevalent. Dr. Junior Matangila from DNDi emphasized the potential of acoziborole to accelerate the elimination of sleeping sickness, stating, “This disease is on the brink of elimination.”
Historical Context and Current Landscape
Sleeping sickness is transmitted through the bite of infected tsetse flies, primarily found in rural sub-Saharan Africa. The disease has historically surged during periods of political instability, with reported cases peaking at nearly 40,000 in 1998. However, due to improved treatments and control measures, reported cases have dramatically declined, with fewer than 600 cases documented in 2024. The World Health Organization (WHO) aims to halt the spread of the most common form of sleeping sickness by 2030.
Clinical Trials and Efficacy
A pivotal study conducted in the DRC and Guinea involved approximately 200 patients, revealing a cure rate exceeding 95% 18 months post-treatment. This high efficacy, coupled with a favorable safety profile, supports the drug's approval and anticipated rollout. Sanofi has committed to donating acoziborole to the WHO, ensuring it will be provided free of charge to patients in endemic regions.
Criticism and Remaining Challenges
Despite the optimism surrounding acoziborole, experts caution that challenges remain. Monica Mugnier, a researcher at Johns Hopkins University, noted that while the drug represents a significant advancement, the complete eradication of the disease is not guaranteed. Questions persist regarding the parasite's potential hiding places, which could hinder elimination efforts.
Future Directions
The approval of acoziborole marks a significant milestone in the fight against sleeping sickness, potentially making it the first infectious disease controlled without a vaccine. Ongoing studies are also assessing the drug's safety and effectiveness in children aged one to 14, further expanding its potential impact.
Verbatim Quotes
- “This disease is on the brink of elimination” — Dr. Junior Matangila, Drugs for Neglected Diseases initiative
- “In just 20 years, we have gone from complicated treatments including arsenic derivatives with serious side effects, to today, when a single-dose, one-day therapy could safely cure patients,” — Dr. Luis Pizarro, Executive Director, DNDi
- “This isn’t solved yet,” — Monica Mugnier, Johns Hopkins University
The introduction of acoziborole represents a pivotal step forward in addressing a disease that has long plagued sub-Saharan Africa, offering hope for a future where sleeping sickness may be eliminated entirely.
